MetLife Investment Management’s ALX Oncology ALXO Stock Holding History

MetLife Investment Management’s Portfolio ALXO Stock Details ALXO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-16,140	Closed	-$97.3K	–	2851
2024 Q2	$97.3K	Buy	16,140 +1,579	+11%	+$19.4K	﹤0.01%	2619
2024 Q1	$162K	Hold	14,561	–	–	﹤0.01%	2308
2023 Q4	$217K	Buy	+14,561	New	+$138K	﹤0.01%	2206
2023 Q3	–	Sell	-11,556	Closed	-$86.8K	–	2896
2023 Q2	$86.8K	Buy	+11,556	New	+$75.6K	﹤0.01%	2761
2023 Q1	–	Sell	-11,755	Closed	-$132K	–	2790
2022 Q4	$132K	Hold	11,755	–	–	﹤0.01%	2472
2022 Q3	$112K	Buy	+11,755	New	+$137K	﹤0.01%	2628
2022 Q2	–	Sell	-10,745	Closed	-$182K	–	2858
2022 Q1	$182K	Buy	10,745 +3,965	+58%	+$67.7K	﹤0.01%	2404
2021 Q4	$146K	Hold	6,780	–	–	﹤0.01%	2256
2021 Q3	$501K	Hold	6,780	–	–	﹤0.01%	1520
2021 Q2	$371K	Hold	6,780	–	–	﹤0.01%	1750
2021 Q1	$500K	Buy	6,780 +2,409	+55%	+$190K	﹤0.01%	1524
2020 Q4	$377K	Hold	4,371	–	–	﹤0.01%	1619
2020 Q3	$165K	Buy	+4,371	New	+$172K	﹤0.01%	1978

Other funds holding ALXO

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MetLife Investment Management's ALXO Position: Q3 2024 in Review

MetLife Investment Management sold out of ALX Oncology (ALXO) in Q3 2024, closing a stake of 16,140 shares — an estimated $97.3K sold.

MetLife Investment Management first reported a position in ALXO in Q3 2020 and held it in 13 quarters. The position peaked at $501K in Q3 2021. 92 funds tracked by Wall St. Rank hold ALXO as of Q3 2024.

MetLife Investment Management reported no remaining ALX Oncology position as of Q3 2024 after selling out during the quarter.
MetLife Investment Management sold 16,140 ALX Oncology shares in Q3 2024, an estimated $97.3K.
MetLife Investment Management first reported a position in ALX Oncology in Q3 2020 and held it in 13 quarters.
MetLife Investment Management's ALX Oncology position peaked at $501K in Q3 2021.
92 funds tracked by Wall St. Rank held ALX Oncology as of Q3 2024.

Based on MetLife Investment Management's 13F filing for Q3 2024, filed 13 Nov 2024.